Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib and Radiation in Squamous Cell Carcinoma of the Skin
NCT00126555Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2005
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gefitinib in squamous cell carcinoma of the skin (SCC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Early Progression Rate at 60 days, Number of Participants With Response Rate at 100 days and 1 more. Started Mar 2005; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the skin (SCC)
Beyond the preview
Go deeper on NCT00126555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126555.